T. Rowe Price Investment Management, Inc. Immatics N.V. Call Options Transaction History
T. Rowe Price Investment Management, Inc.
- $162 Billion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IMTX
# of Institutions
93Shares Held
92.5MCall Options Held
313KPut Options Held
377K-
Wellington Management Group LLP Boston, MA10.4MShares$50.4 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY9.38MShares$45.4 Million2.23% of portfolio
-
Baker Bros. Advisors LP New York, NY7.28MShares$35.2 Million0.57% of portfolio
-
Rtw Investments, LP New York, NY6.54MShares$31.7 Million0.76% of portfolio
-
Vestal Point Capital, LP New York, NY6.28MShares$30.4 Million2.65% of portfolio
About Immatics N.V.
- Ticker IMTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,227,000
- Market Cap $369M
- Description
- Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...